These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
214 related articles for article (PubMed ID: 37456260)
1. The immunomodulatory role of IDO1-Kynurenine-NAD Anu RI; Shiu KK; Khan KH Front Oncol; 2023; 13():1142838. PubMed ID: 37456260 [TBL] [Abstract][Full Text] [Related]
2. Tryptophan: A Rheostat of Cancer Immune Escape Mediated by Immunosuppressive Enzymes IDO1 and TDO. Kim M; Tomek P Front Immunol; 2021; 12():636081. PubMed ID: 33708223 [TBL] [Abstract][Full Text] [Related]
3. Dual-target inhibitors of indoleamine 2, 3 dioxygenase 1 (Ido1): A promising direction in cancer immunotherapy. Zhang Y; Hu Z; Zhang J; Ren C; Wang Y Eur J Med Chem; 2022 Aug; 238():114524. PubMed ID: 35696861 [TBL] [Abstract][Full Text] [Related]
4. Epacadostat stabilizes the apo-form of IDO1 and signals a pro-tumorigenic pathway in human ovarian cancer cells. Rossini S; Ambrosino S; Volpi C; Belladonna ML; Pallotta MT; Panfili E; Suvieri C; Macchiarulo A; Mondanelli G; Orabona C Front Immunol; 2024; 15():1346686. PubMed ID: 38333210 [TBL] [Abstract][Full Text] [Related]
5. Indoleamine 2,3-Dioxygenase 1: A Promising Therapeutic Target in Malignant Tumor. Song X; Si Q; Qi R; Liu W; Li M; Guo M; Wei L; Yao Z Front Immunol; 2021; 12():800630. PubMed ID: 35003126 [TBL] [Abstract][Full Text] [Related]
6. Targeting immunometabolism mediated by the IDO1 Pathway: A new mechanism of immune resistance in endometrial cancer. Passarelli A; Pisano C; Cecere SC; Di Napoli M; Rossetti S; Tambaro R; Ventriglia J; Gherardi F; Iannacone E; Venanzio SS; Fiore F; Bartoletti M; Scognamiglio G; Califano D; Pignata S Front Immunol; 2022; 13():953115. PubMed ID: 36119020 [TBL] [Abstract][Full Text] [Related]
7. Indoleamine 2,3-dioxygenase 1 in circumventing checkpoint inhibitor responses: Updated. Charehjoo A; Majidpoor J; Mortezaee K Int Immunopharmacol; 2023 May; 118():110032. PubMed ID: 36933494 [TBL] [Abstract][Full Text] [Related]
8. Tryptophan depletion sensitizes the AHR pathway by increasing AHR expression and GCN2/LAT1-mediated kynurenine uptake, and potentiates induction of regulatory T lymphocytes. Solvay M; Holfelder P; Klaessens S; Pilotte L; Stroobant V; Lamy J; Naulaerts S; Spillier Q; Frédérick R; De Plaen E; Sers C; Opitz CA; Van den Eynde BJ; Zhu J J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37344101 [TBL] [Abstract][Full Text] [Related]
9. Trial watch: IDO inhibitors in cancer therapy. Le Naour J; Galluzzi L; Zitvogel L; Kroemer G; Vacchelli E Oncoimmunology; 2020 Jun; 9(1):1777625. PubMed ID: 32934882 [TBL] [Abstract][Full Text] [Related]
10. IDO1/TDO dual inhibitor RY103 targets Kyn-AhR pathway and exhibits preclinical efficacy on pancreatic cancer. Liang H; Li T; Fang X; Xing Z; Zhang S; Shi L; Li W; Guo L; Kuang C; Liu H; Yang Q Cancer Lett; 2021 Dec; 522():32-43. PubMed ID: 34520819 [TBL] [Abstract][Full Text] [Related]
11. The catalytic inhibitor epacadostat can affect the non-enzymatic function of IDO1. Panfili E; Mondanelli G; Orabona C; Gargaro M; Volpi C; Belladonna ML; Rossini S; Suvieri C; Pallotta MT Front Immunol; 2023; 14():1134551. PubMed ID: 37122718 [TBL] [Abstract][Full Text] [Related]
12. Tryptophan 2,3-dioxygenase in tumor cells is associated with resistance to immunotherapy in renal cell carcinoma. Sumitomo M; Takahara K; Zennami K; Nagakawa T; Maeda Y; Shiogama K; Yamamoto Y; Muto Y; Nukaya T; Takenaka M; Fukaya K; Ichino M; Sasaki H; Saito K; Shiroki R Cancer Sci; 2021 Mar; 112(3):1038-1047. PubMed ID: 33410234 [TBL] [Abstract][Full Text] [Related]
13. Targeting Indoleamine Dioxygenase and Tryptophan Dioxygenase in Cancer Immunotherapy: Clinical Progress and Challenges. Peng X; Zhao Z; Liu L; Bai L; Tong R; Yang H; Zhong L Drug Des Devel Ther; 2022; 16():2639-2657. PubMed ID: 35965963 [TBL] [Abstract][Full Text] [Related]
14. Both IDO1 and TDO contribute to the malignancy of gliomas via the Kyn-AhR-AQP4 signaling pathway. Du L; Xing Z; Tao B; Li T; Yang D; Li W; Zheng Y; Kuang C; Yang Q Signal Transduct Target Ther; 2020 Feb; 5(1):10. PubMed ID: 32296044 [TBL] [Abstract][Full Text] [Related]
16. Identification and Characterization of a Novel Dual Inhibitor of Indoleamine 2,3-dioxygenase 1 and Tryptophan 2,3-dioxygenase. Yoshioka S; Ikeda T; Fukuchi S; Kawai Y; Ohta K; Murakami H; Ogo N; Muraoka D; Takikawa O; Asai A Int J Tryptophan Res; 2022; 15():11786469221138456. PubMed ID: 36467776 [TBL] [Abstract][Full Text] [Related]
17. Yang D; Zhang S; Fang X; Guo L; Hu N; Guo Z; Li X; Yang S; He JC; Kuang C; Yang Q J Med Chem; 2019 Oct; 62(20):9161-9174. PubMed ID: 31580660 [TBL] [Abstract][Full Text] [Related]
18. Heme-containing enzymes and inhibitors for tryptophan metabolism. Yan D; Lin YW; Tan X Metallomics; 2017 Sep; 9(9):1230-1240. PubMed ID: 28650043 [TBL] [Abstract][Full Text] [Related]
19. Targeting the IDO1 pathway in cancer: from bench to bedside. Liu M; Wang X; Wang L; Ma X; Gong Z; Zhang S; Li Y J Hematol Oncol; 2018 Aug; 11(1):100. PubMed ID: 30068361 [TBL] [Abstract][Full Text] [Related]